Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)

被引：0
|
作者：
Fahmy, Ahmed I. [1 ]
Mekkawy, Mohamed A. [2 ]
Abou-Ali, Adel [3 ]
机构：
[1] Alexandria Univ, Fac Pharm, Alexandria, Egypt
[2] Alexandria Univ, High Inst Publ Hlth, Alexandria, Egypt
[3] King Khalid Univ, Fac Pharm, Abha, Saudi Arabia
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
307
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [1] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [2] Evaluation of New Oral Anticoagulants (NOACs) Bleeding Adverse Reaction Reports in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed
    Mekkawy, Mohamed
    Abou-Ali, Adel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 440 - 441
  • [3] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [4] Evaluation of Spontaneous Adverse Event Reports for Muscle Related Adverse Reactions Attributed to Daptomycin within the FDA Adverse Events Reporting System (FAERS)
    Khedr, Ola F.
    Shokr, Hala
    Mekkawy, Mohamed A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 315 - 315
  • [5] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [7] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [8] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [9] Evaluation of spontaneous adverse event reports for congenital and neonatal birth problems attributed to ondansetron within the FDA adverse events reporting system (FAERS)
    Mekkawy, Mohamed A.
    Khedr, Ola F.
    Shokr, Hala
    Elsobky, Yasmin H.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 230 - 230
  • [10] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
12345